KTRA NASDAQ

Kintara Therapeutics, Inc. operates as a clinical-stage biotechnology firm, dedicated to pioneering and commercializing anti-cancer treatments for patients. Central to its pipeline are two compounds nearing Phase III trials. One, VAL-083, is a DNA-targeting agent developed to combat drug-resistant solid tumors, including challenging conditions like glioblastoma multiforme, alongside other solid tumor types such as ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The other, REM-001, is a photodynamic therapy specifically targeting cutaneous metastatic breast cancer. The company has forged a strategic alliance with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to facilitate the production and sale of VAL-083 within the Chinese market. Incorporated in 2009, Kintara maintains its headquarters in San Diego, California. Its current identity as Kintara Therapeutics, Inc. was adopted in August 2020, succeeding its former name, DelMar Pharmaceuticals, Inc.